Serum levels of S100B and NSE proteins in Alzheimer's disease patients - PubMed (original) (raw)

Serum levels of S100B and NSE proteins in Alzheimer's disease patients

Márcia L Chaves et al. J Neuroinflammation. 2010.

Abstract

Background: Alzheimer's disease is the most common dementia in the elderly, and the potential of peripheral biochemical markers as complementary tools in the neuropsychiatric evaluation of these patients has claimed further attention.

Methods: We evaluated serum levels of S100B and neuron-specific enolase (NSE) in 54 mild, moderate and severe Alzheimer's disease (AD) patients and in 66 community-dwelling elderly. AD patients met the probable NINCDS-ADRDA criteria. Severity of dementia was ascertained by the Clinical Dementia Rating (CDR) scale, cognitive function by the Mini Mental State Examination (MMSE), and neuroimage findings with magnetic resonance imaging. Serum was obtained from all individuals and frozen at -70 degrees C until analysis.

Results: By comparing both groups, serum S100B levels were lower in AD group, while serum NSE levels were the same both groups. In AD patients, S100B levels were positively correlated with CDR scores (rho = 0.269; p = 0.049) and negatively correlated with MMSE scores (rho = -0.33; P = 0.048). NSE levels decreased in AD patients with higher levels of brain atrophy.

Conclusions: The findings suggest that serum levels of S100B may be a marker for brain functional condition and serum NSE levels may be a marker for morphological status in AD.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Serum S100B level (mean ± SD) according to severity of dementia in AD (CDR scale; 1 mild, 2 moderate; 3 severe) - One-way ANOVA (F = 3.685).

Figure 2

Figure 2

Correlation between S100B serum levels and Mini Mental State Examination (MMSE) score: AD patients - Spearman rho = - 0.35; P = 0.01.

Similar articles

Cited by

References

    1. Juva K, Sulkava R, Erkinjuntti T, Ylikoski R, Valvanne J, Tilvis R. Staging the severity of dementia: comparison of clinical (CDR, DSM-III-R), functional (ADL, IADL) and cognitive (MMSE) scales. Acta Neurol Scand. 1994;90:293–298. - PubMed
    1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–1122. doi: 10.1001/archneur.60.8.1119. - DOI - PubMed
    1. Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, Kukull WA. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004;140:501–509. - PubMed
    1. Growdon JH. Biomarkers of Alzheimer disease. Arch Neurol. 1999;56:281–283. doi: 10.1001/archneur.56.3.281. - DOI - PubMed
    1. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, Souza DO, Portela LV, Gentil V. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry. 2007;61:142–144. doi: 10.1016/j.biopsych.2006.03.070. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources